Reports Q4 revenue $3.73B, consensus $3.59B. “I am grateful to our global team, and proud of our exceptional results in 2023,” said Mike Mahoney, chairman and chief executive officer, Boston Scientific. “We are excited about our future and long-range plans as we deliver on our mission to transform patient lives.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BSX:
- Boston Scientific call volume above normal and directionally bullish
- BSX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Boston Scientific price target raised to $70 from $62 at Wells Fargo
- Boston Scientific price target raised to $72 from $62 at Piper Sandler
- Boston Scientific named 2024 Top Pick in MedTech at RBC Capital
